Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
Shares of Zymergen Inc. (NASDAQ:ZY - Get Rating) have been assigned a consensus rating of "Hold" from the six ratings firms that are covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $4.37.
A number of analysts have recently issued reports on ZY shares. UBS Group dropped their price target on shares of Zymergen to $2.60 in a report on Tuesday, July 26th. JPMorgan Chase & Co. raised shares of Zymergen from an "underweight" rating to a "neutral" rating in a report on Tuesday, July 26th.Hedge Funds Weigh In On Zymergen
A number of institutional investors and hedge funds have recently made changes to their positions in ZY. Laurion Capital Management LP purchased a new position in shares of Zymergen in the second quarter worth approximately $37,000. Resolute Advisors LLC bought a new stake in Zymergen during the 2nd quarter worth approximately $49,000. B. Riley Wealth Management Inc. bought a new stake in Zymergen during the 2nd quarter worth approximately $49,000. Virtu Financial LLC raised its stake in Zymergen by 52.5% during the 1st quarter. Virtu Financial LLC now owns 32,312 shares of the company's stock worth $93,000 after acquiring an additional 11,119 shares during the period. Finally, Keebeck Alpha LP bought a new stake in Zymergen during the 1st quarter worth approximately $117,000. Hedge funds and other institutional investors own 52.99% of the company's stock. Zymergen Stock Performance
Shares of ZY stock opened at $2.78 on Friday. Zymergen has a one year low of $1.10 and a one year high of $13.25. The company's 50-day moving average is $2.67 and its 200 day moving average is $2.12. The company has a market capitalization of $290.12 million, a price-to-earnings ratio of -0.78 and a beta of 1.69.
Zymergen (NASDAQ:ZY - Get Rating) last announced its quarterly earnings data on Monday, August 15th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.38). The firm had revenue of $2.63 million for the quarter, compared to analysts' expectations of $3.25 million. Zymergen had a negative net margin of 2,508.94% and a negative return on equity of 93.37%. As a group, research analysts predict that Zymergen will post -2.99 earnings per share for the current fiscal year. Zymergen Company Profile (Get Rating)
Zymergen Inc design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems.Featured ArticlesGet a free copy of the StockNews.com research report on Zymergen (ZY)2 Regional Banks With Sector-Beating Price PerformanceMarketBeat: Week in Review 10/3-10/7ConAgra Brands Is A Value Pick For Income Investors 3 Stocks With Market-Beating Price PerformanceLucid Motors May Test Investors' Resolve, But Should They Sell?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zymergen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymergen wasn't on the list.
While Zymergen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:
Kirk McDonald shares three stocks from different industries with different market caps and explains why each is a holding in his portfolio.
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.